PAH News

September 21, 2020September 21, 2020

Moderna, Chiesi Will Collaborate on New RNA-based Therapies for PAH

News, PAH News

Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH). Messenger RNAs (mRNAs) are the molecules that cells use ... Read more

September 18, 2020September 18, 2020

Study Results Support Opsumit-Adcirca Combo for Newly Diagnosed PAH

News, PAH News

The combination of Opsumit (macitentan) and Adcirca (tadalafil) is a safe and effective initial treatment for pulmonary arterial hypertension (PAH), new clinical trial data show. The findings were published ... Read more

August 31, 2020August 31, 2020

U.S. Patent Approval Expected for LIQ861 Treprostinil Dry Powder

News, PAH News

Liquidia Technologies has received a notice of allowance from the U.S. Patent and Trademark Office, indicating that a patent application for LIQ861, the company’s investigational dry powder formulation of ... Read more

August 17, 2020August 17, 2020

Ambrisentan Ably Treats Chinese Patients with PAH-CTD, Study Reports

News, PAH News

Volibris (ambrisentan) given to treat adults in China with pulmonary arterial hypertension (PAH) caused by connective tissue disease led to significant improvements in exercise capacity without signs of clinical ... Read more

August 12, 2020August 14, 2020

Liquida’s LIQ861 Found to Improve Exercise Capacity, Quality of Life in PAH

News, PAH News

LIQ861, Liquidia Technologies’ proprietary inhaled dry powder formulation of the vasodilator treprostinil, improves exercise capacity and quality of life for people with pulmonary arterial hypertension (PAH), according to data ... Read more

August 10, 2020August 10, 2020

5-year Survival Rate Lower in Congenital Heart Disease Patients With PAH

News, PAH News

The five-year survival rate is markedly reduced among adults with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD), compared with other types of CHD, real-world data from ... Read more

August 7, 2020August 7, 2020

Aerovate Raises $72.6M to Develop Potential PAH Inhaled Therapy AV-101

News, PAH News

Aerovate Therapeutics received $72.6 million in Series A funding to advance trials testing AV-101, an experimental inhaled version of imatinib for the treatment of pulmonary arterial hypertension (PAH). AV-101 is ... Read more

July 29, 2020July 29, 2020

PAH Caused by Undiagnosed Systemic Sclerosis in Case Study

News, PAH News

A case report found a patient’s pulmonary arterial hypertension (PAH) was caused by an undiagnosed case of the autoimmune disorder systemic sclerosis (SSc), highlighting the need for early and thorough ... Read more

July 27, 2020July 27, 2020

Outcomes Better for PAH Patients Treated at Specialty Centers, Study Finds

News, PAH News

People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a lower likelihood of hospitalization, a study reports. These findings support ... Read more

July 22, 2020July 30, 2020

Opsumit Can Lower Mortality Risk in PAH Patients, Study Contends

News, PAH News

When used alone or in combination with other therapies, Opsumit (macitentan) can lower the mortality risk in patients with pulmonary arterial hypertension (PAH), a study found. The study, “Changes ... Read more

Pin It on Pinterest